Target intelligence / Profile preview

Presynaptic cholinergic receptors

Molecular classification
G protein-coupled receptor, Ion channel
01

Overview

Presynaptic cholinergic receptors refer to a heterogeneous group of receptors located on the distal ends of cholinergic neurons that modulate the synthesis and release of acetylcholine (ACh) (Wonnacott, 1997). The primary components include muscarinic autoreceptors, predominantly M2 and M4 subtypes, and nicotinic receptors, such as alpha-7 and alpha-4-beta-2 subtypes (Zhang et al., 2002; UniProt). Muscarinic autoreceptors typically provide negative feedback, inhibiting further ACh release when synaptic concentrations are high, whereas presynaptic nicotinic receptors often facilitate ACh release (StatPearls, 2023). These receptors are critical for maintaining cholinergic homeostasis and are significant in the pathology of neurodegenerative conditions like Alzheimer's disease, where the loss of presynaptic terminals leads to a profound cholinergic deficit (Francis et al., 1999). Pharmacological targeting of these receptors aims to enhance cholinergic transmission, either by blocking inhibitory autoreceptors or by stimulating facilitatory nicotinic receptors (PubMed, 2021).

Other names
Presynaptic cholinergic terminal receptorsCholinergic autoreceptorsPresynaptic muscarinic receptorsPresynaptic nicotinic receptorsPresynaptic acetylcholine receptors
02

Mechanism of action

Modulation of acetylcholine release through feedback inhibition (via M2/M4 muscarinic receptors) or facilitation (via nicotinic receptors) (Zhang et al., 2002; Wonnacott, 1997).

03

Biological functions

Signal transductionNeurotransmitter releaseFeedback inhibitionSynaptic plasticity
04

Disease associations

Neurodegenerative diseaseAlzheimer's diseaseParkinson's diseaseSchizophreniaMyasthenia gravis
05

Safety considerations

Cholinergic syndromeBradycardiaBronchoconstrictionCognitive impairment (with antagonists)Gastrointestinal distress
06

Interacting drugs

Atropine

6 more in the full profile.

07

Biomarkers

[18F]FEOBV PET imaging (marks vesicular acetylcholine transporter as a proxy for terminal density) (PubMed, 2015)Cerebrospinal fluid acetylcholine levels (Francis et al., 1999)Nicotinic receptor PET ligands (e.g., [11C]nicotine) (PubMed, 2021)

Beyond the preview

Go deeper on Presynaptic cholinergic receptors.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Presynaptic cholinergic receptors.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call